title: Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization.
authors.forename: Jose M
authors.initials: JM
authors.lastname: Ruiz-Moreno
authors.forename: Javier A
authors.initials: JA
authors.lastname: Montero
authors.forename: Luis
authors.initials: L
authors.lastname: Arias
authors.forename: Javier
authors.initials: J
authors.lastname: Araiz
authors.forename: Francisco
authors.initials: F
authors.lastname: Gomez-Ulla
authors.forename: Rufino
authors.initials: R
authors.lastname: Silva
authors.forename: David P
authors.initials: DP
authors.lastname: Piñero
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab